Literature DB >> 769631

Leukotactic dystunction in sarcoidosis.

E G Maderazo, P A Ward, C L Woronick, J Kubik, A C DeGraff.   

Abstract

The leukotactic function of patients with sarcoidosis was studied. A defect was found in 19 of the 20 patients tested and was due to moderately elevated serum levels of the chemotactic factor inactivator. The chemotactic factor inactivator levels were not as high as those previously reported in patients with Hodgkin's disease or cirrhosis of the liver. The effect of the inactivator was irreversible and was directed toward all three of the chemotactic factors tested. The physicochemical characteristics of chemotactic factor inactivator in serum from sarcoid patients resembled in most respects the features of chemotactic factor inactivator in normal serum. As expected, the generation of chemotactic activity in some sarcoid serums by zymosan was impaired. The results of this study may relate to some of the reported defects in expression of immunity in sarcoid patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 769631     DOI: 10.7326/0003-4819-84-4-414

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  19 in total

1.  The importance of lymphocytes in pulmonary health and disease.

Authors:  H Y Reynolds
Journal:  Lung       Date:  1978       Impact factor: 2.584

2.  Neutrophil phagocytosis in sarcoidosis. Reduced C3b receptor-mediated phagocytosis in active and silent sarcoidosis.

Authors:  B Schmekel; L Håkansson; R Hällgren; E Nou; G Stålenheim; P Venge
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

3.  Impaired neutrophil function in intestinal lymphangiectasia.

Authors:  R P Bolton; K L Cotter; M S Losowsky
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

4.  Immunologic concepts relating to the pathogenesis of diffuse interstitial lung diseases (emphasizing granulomatous forms and idiopathic pulmonary fibrosis).

Authors:  H Y Reynolds
Journal:  Trans Am Clin Climatol Assoc       Date:  1980

5.  Identification of an IgA inhibitor of neutrophil chemotaxis and its membrane target for the metabolic burst.

Authors:  J N Moy; R D Nelson; K L Richards; M K Hostetter
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

Review 6.  Chemotaxis: basic aspects of methodology, mechanisms and pathology.

Authors:  B M Czarnetzki; E Kownatzki; M Dierich; P C Frei
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

7.  Polymorphonuclear and mononuclear leucocyte function in necrobiosis lipoidica and granuloma annulare.

Authors:  M S Koh; B B Majewski; S Barter; E L Rhodes
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

8.  Kinetic studies of phagocytosis. IV. Cellular defects and humoral inhibition as causes of impaired neutrophil phagocytosis in sarcoidosis.

Authors:  R Hällgren; L Håkansson; B Schmekel; G Stålenheim; P Venge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

9.  Impaired polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis.

Authors:  D H Goddard; A P Kirk; J R Kirwan; G D Johnson; E J Holborow
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

10.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.